<?xml version="1.0" encoding="utf-8" ?>
<INTERACTIONS>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>282-IMMUNOSUPPRESSANTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="IMMUNOSUPPRESSANTS" code="L04A" /></DRUG1>
<DRUG2>
<DRUG name="BOCEPREVIR" rxcui="1102129">
<ATC code="J05AE12" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the blood concentrations of the immunosuppressant (especially for the ciclosporin, extremely large for the tacrolimus)</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Blood concentration dosage of the immunosuppressant, testing of the renal function, and adjustment of the dosage of the immunosuppressant during the administration of the medications together and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>282-IMMUNOSUPPRESSANTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="IMMUNOSUPPRESSANTS" code="L04A" /></DRUG1>
<DRUG2>
<DRUG name="CLARITHROMYCIN" rxcui="21212">
<ATC code="J01FA09" />
</DRUG>
</DRUG2>
<DESCRIPTION>Very large increase of the blood concentrations of the immunosuppressant due to inhibition of its hepatic metabolism</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>If these must be administered together, strict testing of the renal function, blood concentration dosage of the immunosuppressant, and possible adjustment of the dosage. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>282-IMMUNOSUPPRESSANTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="IMMUNOSUPPRESSANTS" code="L04A" /></DRUG1>
<DRUG2>
<CLASS name="CYTOTOXICS" code="L01" /></DRUG2>
<DESCRIPTION>Excessive immunodepression with risk of lymphoproliferative syndrome</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>282-IMMUNOSUPPRESSANTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="IMMUNOSUPPRESSANTS" code="L04A" /></DRUG1>
<DRUG2>
<DRUG name="DALFOPRISTIN" rxcui="229369">
<ATC code="J01FG02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the blood concentrations of the immunosuppressant due to inhibition of its hepatic metabolism.</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Blood concentration dosage of the immunosuppressant, testing of the renal function, and adjustment of the dosage during the treatment with these medications together and after it is stopped.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>282-IMMUNOSUPPRESSANTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="IMMUNOSUPPRESSANTS" code="L04A" /></DRUG1>
<DRUG2>
<DRUG name="DILTIAZEM" rxcui="3443">
<ATC code="C08DB01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the blood concentrations of the immunosuppressant due to decrease of its metabolism</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Blood concentration dosage of the immunosuppressant, testing of the renal function, and adjustment of the dosage during the treatment with these medications together and after it is stopped.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>282-IMMUNOSUPPRESSANTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="IMMUNOSUPPRESSANTS" code="L04A" /></DRUG1>
<DRUG2>
<DRUG name="DRONEDARONE" rxcui="233698">
<ATC code="C01BD07" />
</DRUG>
</DRUG2>
<DESCRIPTION>Large increase of the blood concentrations of the immunosuppressant due to decrease of its metabolism</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>282-IMMUNOSUPPRESSANTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="IMMUNOSUPPRESSANTS" code="L04A" /></DRUG1>
<DRUG2>
<DRUG name="ERYTHROMYCIN" rxcui="4053">
<ATC code="D10AF02" />
<ATC code="D10AF52" />
<ATC code="J01FA01" />
<ATC code="S01AA17" />
</DRUG>
</DRUG2>
<DESCRIPTION>Very large increase of the blood concentrations of the immunosuppressant due to inhibition of its hepatic metabolism</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>If these are administered together, strict testing of the renal function, blood concentration dosage of the immunosuppressant, and possible adjustment of the dosage.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>282-IMMUNOSUPPRESSANTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="IMMUNOSUPPRESSANTS" code="L04A" /></DRUG1>
<DRUG2>
<DRUG name="FLUCONAZOLE" rxcui="4450">
<ATC code="D01AC15" />
<ATC code="J02AC01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the blood concentrations of the immunosuppressant due to the inhibition of its metabolism and of the creatinemia</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Blood concentration dosage of the immunosuppressant, testing of the renal function, and adjustment of the dosage during the administration of the substances together and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>282-IMMUNOSUPPRESSANTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="IMMUNOSUPPRESSANTS" code="L04A" /></DRUG1>
<DRUG2>
<CLASS name="ANTI-LYMPHOCYTE GLOBULINS" code="L04AA0-001" /></DRUG2>
<DESCRIPTION>Excessive immunodepression with risk of lymphoproliferative disorders (LPDs)</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>282-IMMUNOSUPPRESSANTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="IMMUNOSUPPRESSANTS" code="L04A" /></DRUG1>
<DRUG2>
<CLASS name="ENZYMATIC INDUCERS" code="N03-J05-001" /></DRUG2>
<DESCRIPTION>Decrease of the blood concentrations and of the effectiveness of the immunosuppressant, due to increase of its hepatic metabolism by the inducer

</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Increase the dosage of the immunosuppressant according to tests of the blood concentrations. Reduce the dosage after the inducer is stopped.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>282-IMMUNOSUPPRESSANTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="IMMUNOSUPPRESSANTS" code="L04A" /></DRUG1>
<DRUG2>
<CLASS name="RITONAVIR BOOSTED PROTEASE INHIBITORS" code="J05AE-002" /></DRUG2>
<DESCRIPTION>Very large increase of the blood concentrations of the immunosuppressant due to inhibition of its hepatic metabolism</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>If these substances are administered together, strict testing of the renal function, blood concentration dosages of the immunosuppressant, and adjustment of its dosage.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>282-IMMUNOSUPPRESSANTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="IMMUNOSUPPRESSANTS" code="L04A" /></DRUG1>
<DRUG2>
<DRUG name="ITRACONAZOLE" rxcui="28031">
<ATC code="J02AC02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Very large increase of the blood concentrations of the immunosuppressant due to inhibition of its hepatic metabolism</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>If these substances are administered together, strict testing of the renal function, blood concentration dosages of the immunosuppressant, and possible adjustment of the dosage.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>282-IMMUNOSUPPRESSANTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="IMMUNOSUPPRESSANTS" code="L04A" /></DRUG1>
<DRUG2>
<DRUG name="KETOCONAZOLE" rxcui="6135">
<ATC code="D01AC08" />
<ATC code="G01AF11" />
<ATC code="J02AB02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Very large increase of the blood concentrations of the immunosuppressant due to inhibition of its hepatic metabolism.</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>If these substances are administered together, strict testing of the renal function, blood concentration dosages of the immunosuppressant, and possible adjustment of the dosage.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>282-IMMUNOSUPPRESSANTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="IMMUNOSUPPRESSANTS" code="L04A" /></DRUG1>
<DRUG2>
<DRUG name="ST JOHNS WORT" rxcui="258326">
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the blood concentrations of the immunosuppressant, due to the enzymatic inducer effect of the St Johns wort, with risk of reduction of effectiveness, even complete loss of the effect which can have possibly serious consequences (rejection of a graft).</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>282-IMMUNOSUPPRESSANTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="IMMUNOSUPPRESSANTS" code="L04A" /></DRUG1>
<DRUG2>
<DRUG name="NICARDIPINE" rxcui="7396">
<ATC code="C08CA04" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the blood concentrations of the immunosuppressant due to inhibition of its hepatic metabolism</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Blood concentration dosage of the immunosuppressant, testing of the renal function, and adjustment of the dosage of the immunosuppressant during the treatment and after it is stopped.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>282-IMMUNOSUPPRESSANTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="IMMUNOSUPPRESSANTS" code="L04A" /></DRUG1>
<DRUG2>
<DRUG name="GRAPEFRUIT (JUICE AND FRUIT)" >
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the bioavailability of the immunosuppressant and as a result of its undesirable effects. </DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>282-IMMUNOSUPPRESSANTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="IMMUNOSUPPRESSANTS" code="L04A" /></DRUG1>
<DRUG2>
<DRUG name="POSACONAZOLE" rxcui="282446">
<ATC code="J02AC04" />
</DRUG>
</DRUG2>
<DESCRIPTION>Very large increase of the blood concentrations of the immunosuppressant due to inhibition of its hepatic metabolism</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>If these substances are administered together, strict testing of the renal function, blood concentration dosage of the immunosuppressant, and possible adjustment of the dosage.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>282-IMMUNOSUPPRESSANTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="IMMUNOSUPPRESSANTS" code="L04A" /></DRUG1>
<DRUG2>
<DRUG name="PRISTINAMYCIN" rxcui="66958">
<ATC code="J01FG01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the blood concentrations of the immunosuppressant due to inhibition of its hepatic metabolism</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Blood concentration dosage of the immunosuppressant, testing of the renal function, and adjustment of its dosage during the administration of the medications together and after it is stopped.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>282-IMMUNOSUPPRESSANTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="IMMUNOSUPPRESSANTS" code="L04A" /></DRUG1>
<DRUG2>
<DRUG name="QUINUPRISTINE" rxcui="135098">
<ATC code="J01FG02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the blood concentrations of the immunosuppressant due to inhibition of its hepatic metabolism </DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Blood concentration dosage of the immunosuppressant, testing of the renal function, and adjustment of the dosage during the administration of the two substances together and after it is stopped.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>282-IMMUNOSUPPRESSANTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="IMMUNOSUPPRESSANTS" code="L04A" /></DRUG1>
<DRUG2>
<DRUG name="RANOLAZINE" rxcui="35829">
<ATC code="C01EB18" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the blood concentrations of the immunosuppressant due to inhibition of its metabolism by the ranolazine</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical and biological monitoring and possible adjustment of the dosage of the immunosuppressant.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>282-IMMUNOSUPPRESSANTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="IMMUNOSUPPRESSANTS" code="L04A" /></DRUG1>
<DRUG2>
<DRUG name="STIRIPENTOL" rxcui="37119">
<ATC code="N03AX17" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the blood concentrations of the immunosuppressant (decrease of its hepatic metabolism)</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>282-IMMUNOSUPPRESSANTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="IMMUNOSUPPRESSANTS" code="L04A" /></DRUG1>
<DRUG2>
<DRUG name="TELAPREVIR" rxcui="1102261">
<ATC code="J05AE11" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the immunosuppressant due to inhibition of its hepatic metabolism by the telaprevir</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Blood concentration dosage of the immunosuppressant, testing of the renal function, and adjustment of its dosage during the administration of the substances together and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>282-IMMUNOSUPPRESSANTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="IMMUNOSUPPRESSANTS" code="L04A" /></DRUG1>
<DRUG2>
<DRUG name="TELITHROMYCIN" rxcui="274786">
<ATC code="J01FA15" />
</DRUG>
</DRUG2>
<DESCRIPTION>Very large increase of the blood concentrations of the immunosuppressant due to inhibition of its hepatic metabolism</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>If these substances are administered together, strict testing of the renal function, blood concentration dosage of the immunosuppressant, and possible adjustment of the dosage.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>282-IMMUNOSUPPRESSANTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="IMMUNOSUPPRESSANTS" code="L04A" /></DRUG1>
<DRUG2>
<CLASS name="ATTENUATED LIVE VIRUS VACCINES" code="J07B-001" /></DRUG2>
<DESCRIPTION>Risk of general vaccinal disease, possibly fatal. </DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
<COMMENT>And during the 3 months following the treatment. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>282-IMMUNOSUPPRESSANTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="IMMUNOSUPPRESSANTS" code="L04A" /></DRUG1>
<DRUG2>
<DRUG name="VEMURAFENIB" rxcui="1147220">
<ATC code="L01XE15" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of decrease of the concentrations of the immunosuppressants, with the consequence of a risk of ineffectiveness

</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>282-IMMUNOSUPPRESSANTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="IMMUNOSUPPRESSANTS" code="L04A" /></DRUG1>
<DRUG2>
<DRUG name="VORICONAZOLE" rxcui="121243">
<ATC code="J02AC03" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the blood concentrations of the immunosuppressant due to inhibition of its hepatic metabolism by the voriconazole

</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>-with the everolimus, the sirolimus, and the temsirolimus</COMMENT>
</INTERACTION>
</INTERACTIONS>
